Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Quince Therapeutics Inc QNCX

Healthcare Biotechnology
Quince Therapeutics, Inc. is a late-stage biotechnology company. The Company is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. The Company’s asset, EryDex, is being developed for the treatment of a rare neurodegenerative disease, Ataxia-Telangiectasia (A-T). EryDex utilizes a technology platform for autologous... see more

Recent & Breaking News (NDAQ:QNCX)

Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results

Business Wire April 1, 2024

Quince Therapeutics Launches Scientific Advisory Board

Business Wire February 22, 2024

Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors

Business Wire February 15, 2024

Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

Business Wire February 7, 2024

Quince Therapeutics to Participate at Investor Events in January 2024

Business Wire January 4, 2024

Quince Therapeutics Completes Acquisition of EryDel S.p.A.

Business Wire October 23, 2023

U.S. FDA Partial Clinical Hold Lifted on IND for EryDel's Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia

Business Wire September 28, 2023

Quince Therapeutics Appoints Dr. Charles S. Ryan as President

Business Wire September 6, 2023

Quince Therapeutics to Present at Sidoti Virtual Investor Conference on August 17, 2023

Business Wire August 10, 2023

Quince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales Opportunity

Business Wire July 24, 2023

Echo Lake Capital Increase Offer to Acquire Quince Therapeutics, Inc.

Accesswire July 13, 2023

Echo Lake Criticizes Quince Therapeutics Board for Enriching Themselves While Destroying Significant Shareholder Value

Accesswire June 6, 2023

Quince Therapeutics Board of Directors Unanimously Rejects Unsolicited Proposal from Echo Lake Capital

Business Wire April 11, 2023

Quince Therapeutics Engages MTS Health Partners as Independent Financial Advisor

Business Wire April 6, 2023

Quince Therapeutics Adopts Limited Duration Stockholders Rights Plan

Business Wire April 5, 2023

Quince Therapeutics Confirms Receipt of Unsolicited Acquisition Offer from Echo Lake Capital

Business Wire March 22, 2023

Echo Lake Capital Offers to Acquire Quince Therapeutics, Inc.

Accesswire March 21, 2023

Quince Therapeutics Provides Pipeline Update and Business Outlook for 2023

Business Wire January 30, 2023

Quince Therapeutics Completes the Sale of Legacy Protease Inhibitor Portfolio to Lighthouse Pharmaceuticals

Business Wire January 27, 2023

Quince Therapeutics Presents Preclinical Data at MHSRS 2022 Demonstrating Preclinical Efficacy of Bone-targeting Platform for Traumatic Bone Injury

Business Wire September 16, 2022